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Parkin, an E3 ubiquitin ligase implicated in Parkinson’s disease, promotes degradation of dysfunctional mito-
chondria by autophagy. Using proteomic and cellular approaches, we show that upon translocation to mito-
chondria, Parkin activates the ubiquitin–proteasome system (UPS) for widespread degradation of outer
membrane proteins. This is evidenced by an increase in K48-linked polyubiquitin on mitochondria, recruit-
ment of the 26S proteasome and rapid degradation of multiple outer membrane proteins. The degradation
of proteins by the UPS occurs independently of the autophagy pathway, and inhibition of the 26S proteasome
completely abrogates Parkin-mediated mitophagy in HeLa, SH-SY5Y and mouse cells. Although the mitofu-
sins Mfn1 and Mfn2 are rapid degradation targets of Parkin, we ﬁnd that degradation of additional targets
is essential for mitophagy. These results indicate that remodeling of the mitochondrial outer membrane
proteome is important for mitophagy, and reveal a causal link between the UPS and autophagy, the major
pathways for degradation of intracellular substrates.
INTRODUCTION
Parkin and PINK1 are Parkinson’s disease (PD)-related pro-
teins that operate in a common pathway to ensure mitochon-
drial integrity (1–5). Recent studies indicate that Parkin
monitors the quality of the mitochondrial population and trans-
locates from the cytosol onto dysfunctional mitochondria (6–
11). Once on mitochondria, it promotes their degradation via
mitophagy, an autophagic pathway speciﬁc for mitochondria
(8). Loss of this surveillance mechanism presumably contrib-
utes to the accumulation of degenerative mitochondria
observed in Parkin mutant ﬂies (1,2,4).
Molecular models of Parkin function have evolved over the
last decade. Parkin is an E3 ubiquitin ligase (12), and some
disease alleles have impaired enzymatic activity (6,12,13).
Because PD is characterized pathologically by intracellular
proteinaggregatestermedLewybodies,earlymodelspostulated
that Parkin functioned to promote the ubiquitin–proteasome
system(UPS),whichisactivatedbyK48-linkedpolyubiquitina-
tion of substrate proteins (14). Mutation of Parkin would impair
the ubiquitin–proteasome pathway (UPS) of protein degra-
dation, leading tothe toxic accumulation ofmisfolded oraggre-
gated proteins. Since the discovery that Parkin promotes
mitophagy (8), however, recent models have instead empha-
sized the ability of Parkin to mediate K63-linked polyubiquitin
chains, distinct from the classic K48-linked polyubiquitin
chainsassociatedwiththeUPS.Thetopologyofthepolyubiqui-
tinchainlinkagedeterminesthecellularoutcomeofpolyubiqui-
tination (15). It has been shown that the K63-linked
ubiquitination of mitochondrial proteins by Parkin activates
the autophagic machinery through recruitment of ubiquitin
binding adaptors, such as HDAC6 and p62/SQSTM1
(6,13,16). The importance of this mechanism requires clariﬁca-
tion, however, because p62/SQSTM1 null cells have no defect
inParkin-mediated mitophagy(17,18).Thus, thekeymolecular
events occurring between Parkin-mediated ubiquitination of
mitochondrial proteins and the degradation of mitochondria
by the autophagic pathway remain unresolved.
ToelucidatetheproximalfunctionofParkin,weusedquantitat-
iveproteomicstodeﬁne,inanunbiasedandhighlycomprehensive
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to Parkin activity. Our results indicate that in addition to
K63-linked polyubiquitination, the K48-mediated UPS pathway
has a major role in Parkin-dependent mitophagy. We observe
robust recruitment of the 26S proteasome onto mitochondria,
leading to widespread degradation of mitochondrial outer mem-
brane proteins via the UPS. Strikingly, activation of the UPS not
onlyprecedesmitophagy,butisrequiredformitophagy.Inhibition
of the UPS causes complete abrogation of mitophagy.
RESULTS
Parkin activation results in changes to the mitochondrial
proteome
We performed stable isotope labeling by amino acids in cell
culture (SILAC) analysis (19) to monitor changes in the
mitochondrial proteome in a clonal Parkin-expressing HeLa
S3 cell line after a 2 h treatment with carbonyl cyanide
m-chlorophenylhydrazone (CCCP). CCCP dissipates the mito-
chondrial membrane potential, resulting in recruitment of
Parkin to mitochondria and Parkin-dependent mitophagy (8).
With this mass spectrometry-based approach, we quantiﬁed
2979 unique protein groups. Of these, 766 were mapped to
proteins in the human MitoCarta inventory (20), which con-
tains 1013 mitochondrial proteins. This represents a highly
comprehensive coverage of the mitochondrial proteome,
especially given that cultured cell lines express fewer mito-
chondrial proteins than tissues.
To sort through the proteins with altered SILAC ratios, we
set a stringent threshold by considering only those with a
calculated signiﬁcance of ,0.01 (Table 1 and Supplementary
Material, Tables S1–S4). As expected, Parkin was highly
Table 1. Proteins with altered abundance in the mitochondria of CCCP-treated cells
Protein Biological function SILAC ratio
a Signiﬁcance
b
Increased proteins
PARKIN E3 ubiquitin ligase 13 4.42E220
DRP1 Mitochondrial ﬁssion 6.3 4.78E207
Autophagy related
NBR1 Autophagy adaptor 8.3 2.90E206
p62/SQSTM1 Autophagy adaptor 5.8 1.75E206
MAP1LC3B2;MAP1LC3B Autophagosome component 5.4 3.70E206
GABARAPL2 Autophagosome component 3.4 7.87E206
ATP6V1B2 V-type proton ATPase subunit 3.3 1.64E205
ATP6V1E1 V-type proton ATPase subunit 3.1 4.77E203
ATP6V1C1 V-type proton ATPase subunit 2.9 7.23E203
ATP6V1A V-type proton ATPase subunit 2.9 2.45E203
UPS related
Ubiquitin Protein modiﬁcation 8.9 9.58E215
PSMA2 20S proteasome subunit 4.2 8.08E205
PSMB5 20S proteasome subunit 4.2 4.21E204
PSMA1 20S proteasome subunit 4.0 5.38E204
PSMB3 20S proteasome subunit 4.0 6.20E204
PSMB6 20S proteasome subunit 3.9 2.30E204
PSMA6 20S proteasome subunit 3.7 1.18E203
PSMB4 20S proteasome subunit 3.7 1.96E203
PSMA7 20S proteasome subunit 3.7 1.29E203
PSMA4 20S proteasome subunit 3.6 4.70E204
PSMA3 20S proteasome subunit 3.6 4.85E204
PSMB1 20S proteasome subunit 3.3 2.66E203
PSMA5 20S proteasome subunit 3.2 9.68E204
PSMD6 19S proteasome subunit 2.7 6.22E203
PSMD2 19S proteasome subunit 2.5 6.38E203
Decreased proteins
c
MFN1 Mitochondrial fusion 0.09 6.94E218
MFN2 Mitochondrial fusion 0.10 2.51E235
TOM70 Mitochondrial import 0.13 3.78E240
MIRO1/RHOT1 Mitochondrial transport 0.16 4.29E215
CPT1A Fatty acid metabolism 0.23 1.62E221
MOSC2 Oxidoreductase 0.26 6.67E210
MITONEET/CISD1 Regulation of respiration 0.26 8.74E218
GPAM Glycerolipid synthesis 0.42 3.39E204
MIRO2/RHOT2 Mitochondrial transport 0.44 4.94E206
FIS1 Mitochondrial ﬁssion 0.55 1.33E203
Summary of the most signiﬁcantly altered proteins in mitochondria isolated from Parkin-expressing HeLa S3 cells after treatment with or without CCCP for 2 h.
aCombined SILAC ratio from three independent mass spectrometry experiments consisting of two independent biological samples, and one technical replicate. In
one of the experiments, the SILAC cells were reverse labeled with SILAC. The ratio represents the protein level in mitochondria of CCCP-treated cells divided by
the level in untreated cells.
bCorresponds to the signiﬁcance calculated in MaxQuant.
cOnly MitoCarta proteins annotated as ’outer membrane proteins’ in Uniprot are shown.
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Consistent with studies indicating that Parkin translocation
leads to mitophagy, we found enrichment of several
autophagy-related proteins, including p62/SQSTM1, NBR1,
LC3 and the LC3 family member GABARAPL2. In addition,
we found an increase in several subunits of the V-type proton
ATPase, which is a component of acidic organelles, such as
endosomes and lysosomes. The mitochondrial ﬁssion factor
Drp1 was also substantially enriched, and probably contributes
to the fragmentation of mitochondria observed after CCCP
treatment.
In addition to the autophagy pathway, the SILAC data
provided evidence for a major induction of the ubiquitin–
proteasome system (UPS). Firstly, ubiquitin was 9-fold more
abundant in the mitochondria of CCCP-treated cells
(Table 1). Secondly, numerous subunits of the proteasome
were identiﬁed as enriched. This included subunits of both
the 20S core particle and the 19S regulatory particle, thereby
suggesting that 26S proteasomes are recruited to
CCCP-treated mitochondria. Finally, we found a number of
mitochondrial proteins that were substantially under-
represented after CCCP treatment. Among them, there are pro-
teins from all four mitochondrial sub-compartments. Because
Parkin translocates to the surface of mitochondria, we
focused on outer membrane proteins, which are more likely
to represent proximal effects of Parkin translocation.
Mitochondrial outer membrane proteins were over-
represented in the list of mitochondrial proteins with
reduced abundance (Table 1). Although mitochondrial outer
membrane proteins make up only 5% of the quantiﬁed mito-
chondrial proteins in our SILAC experiment, they constitute
20% of the reduced abundance proteins (P ¼ 0.00014). The
most severely reduced outer membrane proteins include the
mitofusins Mfn1 and Mfn2, which mediate mitochondrial
fusion. In addition, Miro1 and Miro2, which are involved in
mitochondrial transport along microtubules, are also highly
reduced. These data, along with the increase in Drp1,
support the recent suggestion that Parkin, as part of a quality
control mechanism, may serve to restrict defective mitochon-
dria from fusing with neighboring mitochondria (11,21).
Although several proteins involved in mitochondrial dynamics
are degraded by Parkin, the list of rapidly degraded mitochon-
drial proteins is broad and includes ones involved in protein
import and various biosynthetic pathways. For example, the
mitochondrial import receptor subunit Tom70 is one of the
most severely reduced proteins.
Parkin promotes degradation of mitochondrial outer
membrane proteins
To extend these ﬁndings, we used immunoblotting to monitor
the abundance of speciﬁc mitochondrial proteins in response
to CCCP treatment. In agreement with our SILAC data, we
found rapid degradation of Mfn1, Mfn2 and Tom70 upon
CCCP treatment of Parkin-expressing cells (Fig. 1A).
Almost complete degradation of these proteins occurred
within the ﬁrst hour of CCCP treatment. Such degradation
was dependent on Parkin, because the levels of Mfn1, Mfn2
and Tom70 remained unchanged with CCCP in the parental
HeLa S3 cells (Fig. 1A), which do not express Parkin (Sup-
plementary Material, Fig. S1A). Similarly, we found Parkin-
dependent degradation of other outer membrane proteins,
Figure 1. Parkin mediates extensive proteolysis of outer membrane proteins via the UPS. (A) Parkin- and CCCP-dependent proteolysis of mitochondrial outer
membrane proteins. HeLa S3 cells or clonal Parkin-expressing HeLa S3 cells were treated with vehicle or 20 mM CCCP to dissipate the mitochondrial membrane
potential. Total cell lysates at the indicated time points were analyzed by immunoblotting for the indicated proteins. Outer membrane proteins: Mfn1, Mfn2,
Tom70, VDAC1, Bak, Fis1, Tom20. Intermembrane space protein: cytochrome c. Inner membrane protein: Opa1. Matrix proteins: Hsp60, Sod2, F1b.
Loading control: actin. (B) Inhibition of outer membrane protein degradation by the proteasome inhibitor MG132. Immunoblot analysis of Mfn1, Mfn2,
VDAC1, Tom20 and actin (loading control) levels after CCCP with or without treatment with the proteasome inhibitor MG132 (10 mM). (C) Inhibition of
outer membrane protein degradation by the proteasome inhibitor epoxomicin. Same as (B), except epoxomicin (2 mM), a more speciﬁc proteasome inhibitor,
was used.
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of mitochondrial activities, including solute transport
(VDAC1), regulation of apoptosis (Bak), mitochondrial
ﬁssion (Fis1) and protein import (Tom20). Because of the
slower kinetics, some of these proteins were not identiﬁed as
reduced in the SILAC experiment, where cells were analyzed
after 2 h of CCCP treatment. For Bak and Fis1, higher molecu-
lar weight species appeared after CCCP treatment (asterisks,
Fig. 1A). No signiﬁcant changes were observed for several
mitochondrial matrix proteins, as well as the intermembrane
space protein cytochrome c. In addition, there was only a
slight reduction in the short isoforms of Opa1, an inner mem-
brane protein. As reported previously, the long isoform of
Opa1 is degraded in response to CCCP treatment (22,23),
but in a Parkin-independent manner.
To determine whether the observed Parkin-mediated degra-
dation of outer membrane proteins is dependent on the UPS,
we incubated cells with proteasome inhibitors before treatment
with CCCP (Fig. 1B and C). Indeed, inhibition of the protea-
some with either MG132 or epoxomicin substantially blocked
the degradation of Mfn1, Mfn2, VDAC1 and Tom20. In the
case of Mfn1, Mfn2 and VDAC, this treatment also resulted
in higher molecular weight species (asterisks, Fig. 1B and
C). Therefore, we conclude that a proximal function of
Parkin recruitment to depolarized mitochondria is to mediate
the proteasome-dependent degradation of multiple mitochon-
drial outer membrane proteins. The degradation of outer mem-
brane proteins was less efﬁcient in HeLa cells expressing the
R275W mutant, which has a partial defect in ubiquitination
(Supplementary Material, Fig. S1B) (6).
We obtained similar protein degradation proﬁles by treating
cells with valinomycin, a potassium ionophore that dissipates
the electric potential across the inner membrane of mitochon-
dria (Supplementary Material, Fig. S1C). In contrast, treat-
ment with the complex I inhibitor rotenone did not result in
outer membrane protein degradation (Supplementary Material,
Fig. S1C). These results support the view that Parkin is acti-
vated by severe mitochondrial depolarization, rather than by
mitochondrial dysfunction per se (24). Indeed, Parkin does
not localize to mitochondria upon treatment with rotenone
(25).
Degradation of outer membrane proteins occurs
independently of autophagy
As in HeLa cells, expression of Parkin in mouse embryonic
ﬁbroblasts (MEFs) results in CCCP-induced mitophagy
(8,17,18,26). We took advantage of the genetic tractability
of this system to determine whether Parkin-dependent degra-
dation of mitochondrial outer membrane proteins occurs
independently of the autophagy pathway. Atg3 is an E2-like
enzyme that is essential for conjugation of Atg8/LC3 to
phosphatidylethanolamine, an early step in the induction of
autophagosomes. Atg3-null MEFs do not show LC3 conju-
gation and are defective in autophagy (27). We found that
Parkin-expressing Atg3-null MEFs underwent mitochondrial
outer membrane protein degradation in response to CCCP
(Fig. 2A). This degradation was blocked by epoxomicin
(Fig. 2B). These results indicate that Parkin-mediated degra-
dation of outer membrane proteins occurs via the proteasome
and independently of the autophagy pathway.
Recruitment of the proteasome to depolarized
mitochondria
The UPS is classically associated with polyubiquitination via
the K48 residue of ubiquitin (15). In our SILAC analysis,
we found a substantial increase in both K48-linked (9-fold)
and K63-linked (28-fold) polyubiquitination in mitochondria
of cells treated with CCCP (Fig. 3A). We independently con-
ﬁrmed these mass spectrometric observations by immunoblot
analysis using anti-polyubiquitin antibodies that are linkage
speciﬁc (Fig. 3B). The increases in K48-linked and K63-
linked polyubiquitin are both Parkin- and CCCP-dependent.
Our SILAC data also indicated the accumulation of multiple
26S proteasome subunits to CCCP-treated mitochondria
Figure 2. Proteolysis of the outer membrane occurs independently of the autophagy pathway. (A) CCCP-dependent degradation of mitochondrial outer membrane
proteins in Atg3-null MEFs expressing Parkin. Atg3-null MEFs expressing EGFP-Parkin were treated with dimethyl sulfoxide (DMSO) (vehicle) or 20 mM CCCP for
the indicated time. Total cell lysates were isolated and immunoblotted against the indicated proteins. (B) Inhibition of outer membrane protein degradation by the
proteasome inhibitor epoxomicin. Atg3-null MEFs expressing EGFP-Parkin were treated with DMSO (vehicle) or the proteasome inhibitor epoxomicin (2 mM)f o r
2 h prior to treatment with 20 mM CCCP for the indicated times. Total cell lysates were isolated and immunoblotted against the indicated proteins.
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against a and b subunits of the proteasome. In Parkin-expres-
sing HeLa cells, the anti-proteasome staining was diffusely
cytosolic, but a clear enrichment on mitochondria was found
upon CCCP treatment (Fig. 3C and D).
Degradation of mitochondrial outer membrane proteins
precedes mitophagy
Given our ﬁnding that Parkin mediates proteolysis of outer
membrane proteins, we investigated the temporal relationship
of this process to mitophagy. We compared the behavior of the
outer membrane marker Tom20 to the matrix marker Hsp60,
which is not degraded by the UPS (Fig. 1A). When
Parkin-expressing HeLa cells were treated with CCCP for
4 h, two populations of mitochondria could be distinguished
(Fig. 4A). The bulk of the mitochondria aggregated around
the perinuclear region, consistent with previous studies
(6,10,17). These perinuclear aggregates were positive for
both Tom20 and Hsp60, although discrete patches were nega-
tive for Tom20 (Fig. 4B, ﬁlled arrowhead). The second popu-
lation consisted of individual mitochondria dispersed in the
cell periphery. Remarkably, in all cells, this second mitochon-
drial population was strongly positive for Hsp60, but devoid of
any Tom20 signal (Fig. 4A and B). These results indicate that
the loss of Tom20 is distinct from mitophagy. Both the
Figure 3. Parkin activation results in mitochondrial K48-linked and K63-linked polyubiquitination and proteasome recruitment. (A) The SILAC ratio for
K48-linked and K63-linked polyubiquitination obtained from mass spectrometric analysis of mitochondria isolated after 2 h of CCCP treatment. Both modiﬁ-
cations yield unique diglycine signature peptides that can be quantiﬁed (41). Mitochondria were isolated under conditions where the activity of the 26S protea-
some was not inhibited. (B) Accumulation of K48- and K63-linked polyubiquitinated proteins in mitochondria of CCCP-treated cells. Immunoblot analysis of
mitochondria isolated from HeLa S3 or Parkin-expressing HeLa S3 cells, with or without CCCP treatment. Blots were probed with the following antibodies:
anti-ubiquitin, anti-K48-linked polyubiquitin, anti-K63-linked polyubiquitin and anti-F1b (loading control). Puriﬁed polyubiquitin chains of the K48-linked
or K63-linked type were used as controls to verify the speciﬁcity of the antibodies used. Cells were pretreated with the proteasome inhibitor MG132
(10 mM) together with CCCP, and mitochondria were isolated in the presence of N-ethylmaleimide (10 mM) to prevent deubiquitination. (C) Analysis of protea-
some localization. HeLa cells expressing Parkin were treated with DMSO (vehicle) or 20 mM CCCP for 4 h. Formalin-ﬁxed cells were stained for the b subunit
PSMB5 of the proteasome (green), Hsp60 (red) and nuclei [4′,6-diamidino-2-phenylindole (DAPI), blue]. (D) Same as (C), except cells were immunostained for
PSMA2 (green), an a subunit of the proteasome.
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dependent, as these events do not occur in HeLa cells
lacking Parkin (Supplementary Material, Fig. S3A).
Later time points showed an even more dramatic discre-
pancy between Tom20 and Hsp60 staining. After 24 h of
CCCP treatment,  20% of the cells showed complete loss
of Tom20 immunostaining (Fig. 4A), consistent with previous
studies. Among these cells,  40% have no detectable Hsp60
signal, whereas the other  60% retained strong Hsp60
signals despite an obvious reduction in overall mitochondrial
biomass (Fig. 4A and C). The above observations are not
speciﬁc to Hsp60, as immunostaining against two independent
matrix proteins, TRAP-1 (Supplementary Material, Fig. S3B)
and F1b (Supplementary Material, Fig. S3C), revealed a
Figure 4. Degradation of Tom20 occurs prior to mitophagy and does not require the autophagy pathway. (A) Degradation of Tom20 induced by CCCP treatment.
After 4 and 24 h of CCCP (20 mM) or vehicle treatment, HeLa cells expressing Parkin were stained for Hsp60 (green), Tom20 (red) and nuclei (DAPI, blue). In
the second row, the insets show enlarged views of the boxed area. Arrowheads mark examples of dispersed mitochondria that are positive for Hsp60 but negative
for Tom20. In the fourth row, the asterisk indicates a cell with Tom20-negative/Hsp60-positive mitochondria. (B) Loss of Tom20 in both dispersed mitochondria
and within patches of the mitochondrial aggregate. HeLa cells expressing Parkin were treated with CCCP for 4 h and stained for Hsp60 (green), Tom20 (red) and
nuclei (DAPI, blue). The lower three panels correspond to the boxed area in the top panel. The ﬁlled arrowhead marks a patch in the perinuclear mitochondrial
aggregate that is positive for Hsp60, but negative for Tom20. Unﬁlled arrowheads mark dispersed mitochondria that are Tom20 negative/Hsp60 positive. (C)
Quantitation of the 24 h time point in (A). Cells that were Tom20 negative were scored for Hsp60 immunoreactivity. Error bars indicate standard deviations from
three independent experiments; 100 cells were scored per experiment. (D) Tom20 degradation in Atg3-null MEFs. Wild-type and Atg3-null MEFs expressing
EGFP-Parkin were treated with 20 mM CCCP for 24 h and immunostained for Tom20 or Hsp60. Cells were scored for complete loss of Tom20 or Hsp60. Repre-
sentative images of Atg3-null cells are shown on the right. The left image shows an example of a Tom20-negative cell (asterisk). No Hsp60-negative cells were
ever found (right image). Error bars represent standard deviations from three independent experiments; 100 cells were analyzed per experiment. The P-value was
calculated using the t-test. All scale bars are 10 microns.
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membrane protein Tom20 as a marker to monitor loss of mito-
chondria through Parkin-mediated mitophagy (6,8,9,13). Our
observations indicate that, in some cases, the loss of Tom20
staining reﬂects Tom20 degradation by the UPS, rather than
frank removal of the organelle. Our data therefore provide evi-
dence that the Parkin-mediated proteolysis of outer membrane
proteins precedes, and is distinct from, degradation of mito-
chondria via mitophagy.
We compared wild-type versus autophagy-deﬁcient
Atg3-null MEFs to further clarify the distinction between
outer membrane protein degradation and mitophagy. After
CCCP treatment, Parkin-expressing Atg3-null MEFs failed
to undergo mitophagy (as indicated by preservation of
Hsp60 staining) but still showed loss of Tom20 staining
(Fig. 4D). These observations clearly demonstrate that degra-
dation of mitochondrial outer membrane proteins, but not
mitophagy, occurs independently of the autophagy machinery.
The UPS is essential for Parkin-mediated mitophagy
When Parkin-expressing cells were treated with CCCP for 4 h,
dispersed mitochondria at the cell periphery are Tom20 nega-
tive but Hsp60 positive (Figs 4A and B and 5B). Intriguingly,
the autophagosome marker LC3B is selectively associated
with these dispersed mitochondria (Fig. 5A). LC3B is
present in  90% of the dispersed mitochondria, but generally
absent from the aggregated mitochondria. Treatment with the
proteasome inhibitor MG132 prevented the formation of dis-
persed, Tom20 negative, mitochondria at 4 h after CCCP treat-
ment (Fig. 5B), without affecting the recruitment of Parkin to
mitochondria (Supplementary Material, Fig. S4A and B).
Quantiﬁcation showed that, in the absence of MG132,
 90% of CCCP-treated cells show 30 or more Tom20-
negative mitochondria that are dispersed in the cell periphery
(Fig. 5B). In contrast, .90% of MG132-treated cells show no
dispersed, Tom20-negative mitochondria (Fig. 5B). Similar
results were obtained with epoxomicin (Supplementary
Material, Fig. S4C and D). To understand the dynamics of
Tom20 loss, we performed additional immunostaining exper-
iments at early time points after CCCP treatment. In the
absence of epoxomicin treatment, some Tom20-negative mito-
chondria arise prior to the overt perinuclear aggregation of
mitochondria (Supplementary Material, Fig. S3D). After
aggregation of the mitochondria, Tom20-negative mitochon-
dria continue to accumulate. The latter observation suggests
that the 26S proteasome may facilitate dispersion of mitochon-
dria from the perinuclear aggregate, and thereby their uptake
by the autophagy machinery. In addition, however, it is clear
that Tom20-negative mitochondria can also arise without
ﬁrst being part of the perinuclear mitochondrial aggregate.
Because Parkin-dependent proteolysis occurs prior to mito-
phagy, we asked whether this proteolysis is functionally
coupled to mitophagy. When cells are treated with a
100 min pulse of CCCP and allowed to recover for 12 h,
.90% of the cells show highly fragmented and dispersed
mitochondria (Fig. 5C). By 24 h,  30% of the cells show
complete loss of mitochondria, reﬂecting a high level of mito-
phagy (Fig. 5D). Pretreatment of cells with MG132 or epoxo-
micin dramatically changed the cellular outcome of the CCCP
pulse. At 12 h, the cells showed an obvious preservation of
mitochondria mass and tubular mitochondria, compared with
cells without MG132 or epoxomicin (Fig. 5C and Supplemen-
tary Material, Fig. S4C and E). Most remarkably, at 24 h, all
cells treated with MG132 or epoxomicin retained abundant
mitochondria (Fig. 5D), indicating that the 26S proteasome
is critical for Parkin-mediated mitophagy. Inhibition of the
proteasome also blocked mitophagy in MEFs expressing
Parkin (Supplementary Material, Fig. S4G). The degradation
of mitochondria was reduced in HeLa cells overexpressing
the K48R ubiquitin mutant (Supplementary Material,
Fig. S2), consistent with the idea that K48-linked polyubiqui-
tination is involved in Parkin-mediated mitophagy.
To determine whether these results apply to neuronal cells,
we utilized the dopaminergic neuroblastoma cell line
SH-SY5Y, which also undergoes CCCP-induced mitophagy
upon expression of Parkin (6). As in HeLa cells, CCCP treat-
ment of Parkin-expressing SH-SY5Y cells led to, at 4 h post-
treatment, the appearance of peripheral mitochondria that were
Tom20 negative but Hsp60 positive. Treatment with epoxomi-
cin prevented the appearance of such Tom20-negative mito-
chondria (Fig. 5E and Supplementary Material, Fig. S4F). At
24 h post-CCCP treatment, epoxomicin also completely
blocked mitophagy in the SH-SY5Y cells (Fig. 5F and Sup-
plementary Material, Fig. S4F).
Because Mfn1 and Mfn2 are rapidly degraded downstream
of Parkin in response to mitochondrial depolarization, we
wondered whether inhibition of their degradation was respon-
sible for the ability of proteasome inhibitors to block Parkin-
mediated mitophagy. To address this issue, we tested
whether epoxomicin could inhibit Parkin-mediated mitophagy
in Mfn-null MEFs that lack both Mfn1 and Mfn2. We found
that mitophagy in these cells, as in wild-type MEFs, was
still completely blocked by epoxomicin (Fig. 6), indicating
that degradation of proteins beyond Mfn1 and Mfn2 are essen-
tial for mitophagy caused by Parkin activation.
DISCUSSION
Previous studies showed that, upon recruitment to dysfunc-
tional mitochondria, Parkin predominantly mediates
K63-linked polyubiquitination, which facilitates recruitment
of the autophagic adaptor p62 (6,13,16–18). However, p62
appears to be involved in controlling mitochondrial distri-
bution and is not essential for degradation of mitochondria
(17,18). In addition to the enrichment of K63-linked polyubi-
quitination, our proteomics and biochemical experiments
revealed signiﬁcant enrichment of K48-linked polyubiquitina-
tion, which is the linkage-type that classically targets proteins
for degradation via the UPS. Given the rapid degradation of
K48-linked proteins, effective detection of this type of polyu-
biquitination requires sensitive methods such as mass spec-
trometry, unless degradation of K48-linked proteins is
prevented by inhibition of the UPS. Thus, it is not surprising
that the role of K48-polyubiquitination in Parkin-mediated
mitophagy was previously underappreciated. Taken together,
these results indicate a dual molecular function for the ubiqui-
tin ligase activity of Parkin. Polyubiquitination of mitochon-
drial proteins is used as an interaction module to recruit the
1732 Human Molecular Genetics, 2011, Vol. 20, No. 9autophagic machinery, as well as a signal for outer membrane
protein degradation.
Several recent studies have focused on mitofusins as a
degradation target of Parkin. In Drosophila, mitofusin
(dmfn) is ubiquitinated and downregulated by Parkin
(11,21). This relationship may underlie, in part, the strong
genetic interactions between mitochondrial fusion/ﬁssion
and the Pink1/Parkin pathway (28–30). In mammals,
Mfn1 and Mfn2 are polyubiquitinated (31) and degraded
(32) in response to Parkin activation. These studies in mam-
malian and Drosophila cells suggest that degradation of
mitofusins may serve to segregate dysfunctional
Figure 5. Activation of the ubiquitin–proteasome pathway is essential for mitophagy. (A) Co-localization of dispersed mitochondria and LC3B in CCCP-treated
cells. HeLa cells expressing Parkin and EGFP-LC3B were treated with 100 nM baﬁlomycin A1 and CCCP for 4 h, and stained for Hsp60 (red), EGFP-LC3B
(green) and nuclei (DAPI, blue). Enlarged views of the boxed area are shown in the right column. Filled arrowheads mark examples of co-localization
between dispersed mitochondria and EGFP-LC3B. The unﬁlled arrowhead marks an example of a dispersed mitochondrion that does not co-localize with
EGFP-LC3B. Quantitation of this experiment is shown in the graph below. Error bars represent standard deviations from three independent experiments.
Twenty cells were analyzed for each replicate, and  2400 dispersed mitochondria were manually assessed in total. In (B)–(D), Parkin-expressing HeLa
cells were treated with CCCP in the presence or absence the proteasome inhibitor MG132 (10 mM). Cells were immunostained for Hsp60 (green), Tom20
(red) and nuclei (DAPI, blue). (B) MG132 inhibits Tom20 loss after 4 h of persistent CCCP treatment. Inset shows an enlarged view of the boxed area, high-
lighting the presence of dispersed, Tom20-negative mitochondria when MG132 is not present. The graph on the right shows quantiﬁcation of this experiment.
Each cell was scored into one of the ﬁve indicated bins, depending on the number of dispersed mitochondria that are Tom20 negative, but Hsp60 positive. Error
bars indicate standard deviations from three independent experiments; 100 cells were scored per experiment. (C) MG132 preserves mitochondrial morphology at
12 h after a 100 min pulse treatment with CCCP. The graph on the right shows quantiﬁcation of mitochondrial morphology. Cells were scored as having tubular
mitochondria, fragmented mitochondria or no mitochondria. Error bars indicate standard deviations from three independent experiments; 500 cells were scored
per experiment. (D) MG132 or epoxomicin abrogates CCCP-induced mitophagy. The images show cells 24 h after a 100 min pulse treatment with CCCP in the
presence or absence of MG132 (10 mM). The graph on the right shows quantiﬁcation of this experiment and a related one with epoxomicin (2 mM). Cells without
mitochondria were deﬁned by the complete lack of both Tom20 and Hsp60 signal. Error bars indicate standard deviations from three independent experiments.
1000 cells were scored for each MG132 experiment, and 200 cells were scored for each epoxomicin experiments. Scale bars equal 10 mm for (A)–(D). (E)
Degradation of Tom20 in human neuroblastoma SH-SY5Y cells expressing exogenous Parkin. Cells were treated with DMSO (vehicle) or CCCP (20 mM)
for 4 h. Cells were scored into one of the indicated ﬁve bins, depending on the number of dispersed mitochondria lacking Tom20, as described for (B).
Error bars indicate standard deviations in three independent experiments; 100 cells were scored per experiment. (F) Epoxomicin abrogates CCCP-induced mito-
phagy in SH-SY5Y cells expressing Parkin. Cells were treated as in (D) in the presence or absence of epoxomicin (2 mM) and stained for Hsp60 and nuclei
(DAPI). Cells without mitochondria were identiﬁed by complete loss of Hsp60 signal around the DAPI-stained nucleus. Error bars represent standard deviations
from three independent experiments; 200 cells were analyzed per experiment.
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mitophagy (32–34).
During preparation of this manuscript, it was reported that
Parkin-mediated degradation of mitofusins is prevented by
over-expression of dominant-negative p97 or the proteasome
inhibitor MG132 (32). Inhibition of either p97 or the protea-
some also blocks mitophagy, but it is unclear whether this
effect is due to the prevention of mitofusin degradation (32).
Given that inhibition of the proteasome inhibits mitophagy,
it is important to characterize the role of the UPS in this
pathway and to evaluate whether mitofusins are the critical
degradation targets of Parkin. Our proteomics and cell biologi-
cal experiments demonstrate robust recruitment of the 26S
proteasome to mitochondria and enrichment of K48-linked
polyubiquitin, thus supporting a direct role of the UPS in
Parkin-mediated mitophagy. In addition to mitofusins, we
identiﬁed a broad range of mitochondrial outer membrane pro-
teins that are degraded in a Parkin- and UPS-dependent
manner. Importantly, we ﬁnd that Parkin-mediated mitophagy
in Mfn1/Mfn2-null cells is still blocked by inhibition of the
proteasome. Therefore, although degradation of mitofusins
may indeed serve to segregate dysfunctional mitochondria,
our results provide strong evidence that additional remodeling
of the mitochondrial outer membrane proteome, involving
widespread proteolysis, is necessary to promote mitophagy.
As a technical point, we note that accurate assessment of mito-
phagy in future studies will require the use of a marker protein
located in the mitochondrial matrix, and not an outer mem-
brane protein such as the commonly used Tom20.
Further work will be necessary to understand mechanisti-
cally how the UPS facilitates mitophagy. Two general
models, not mutually exclusive, can be proposed. First,
removal of outer membrane proteins may facilitate engulfment
of mitochondria by autophagosomes. We speculate that aggre-
gation of depolarized mitochondria depends on outer mem-
brane proteins, and that degradation of such proteins by the
UPS may help disperse mitochondria into small individual
units so that they can be substrates for autophagy. This
model is consistent with the broad degradation of outer mem-
brane proteins by Parkin, and the observation that fragmenta-
tion of mitochondria is important for mitophagy (35).
Alternatively, Parkin-mediated degradation may serve to
remove one or more negative regulators of mitophagy on the
mitochondrial surface, thereby triggering a signal for engulf-
ment of a defective mitochondrion by an autophagosome.
By linking Parkin-mediated polyubiquitination to the UPS,
our results support, in a general sense, earlier models postulat-
ing a role for Parkin in cellular protein quality control (14). In
PD and other neurodegenerative disorders—including Alzhei-
mer’s, prion and polyglutamine diseases—defects in the UPS
are thought to contribute to toxic accumulation of misfolded or
aggregated proteins in the cytosol (14,36). Distinct from these
earlier models, however, we show that for Parkin, the UPS
operates within a separate cellular pathway involving mito-
chondrial quality control.
Our results provide evidence for the concept that the two
major degradative pathways—the UPS and autophagy—are
functionally linked (37). In future studies, it will be important
to explore whether activation of the UPS is important for other
forms of autophagy. In addition, although the UPS is clearly
essential for Parkin-mediated mitophagy, it remains possible
that activation of the UPS by Parkin has additional functions
for mitochondria. Clariﬁcation of this issue will have impor-
tant implications for the pathogenesis of PD.
MATERIALS AND METHODS
Cell culture and stable isotope labeling by amino acid
in cell culture (SILAC)
Parkin-expressing cell lines were generated via lentivirus-
mediated transduction of HeLa S3, HeLa cells and
SH-SY5Y cells, followed by isolation of clones where indi-
cated. Expression of Parkin is driven from the cytomegalo-
virus promoter. The wild-type and Atg3-null MEFs were
kindly provided by Yu-Shin Sou and Masaaki Komatsu (27).
Enhanced green ﬂuorescent protein (EGFP)-tagged mouse
Parkin was expressed in MEFs via retrovirus-mediated trans-
duction, and EGFP-Parkin-expressing cells were selected by
G418 (400 mg/ml). HeLa, HeLa S3 and MEF cell lines were
cultured in Dulbeco’s modiﬁed Eagle’s medium (DMEM)
containing 10% bovine serum (for HeLa and HeLa S3), or
10% fetal bovine serum supplemented with non-essential
amino acids (for MEFs). For SILAC, DMEM lacking arginine
and lysine was used, along with 10% dialyzed fetal bovine
serum. For heavy labeling, Arg6 (U-13C6) and Lys8
(U-13C6, U-15N2) (Cambridge Isotopes) were supplemented
at the same concentration as in the standard DMEM formu-
lation. For light labeling, regular DMEM was used.
To dissipate the mitochondrial membrane potential, 20 mM
carbonyl cyanide CCCP (Sigma) was used. For pulse treat-
ments, cells were incubated in media with 20 mM CCCP for
100 min, followed by incubation in media without CCCP for
the indicated time. For inhibition of the proteasome, cells
were pretreated with 10 mM MG132 (Sigma), or 2 mM epoxo-
micin (Sigma) prior to treatment with CCCP.
Figure 6. Parkin-mediated mitophagy in Mfn-null cells is blocked by the pro-
teasome inhibitor epoxomicin. EGFP-Parkin was expressed in wild-type (WT)
and Mfn1/Mfn2-null MEFs containing matrix-targeted TagRFP-T. Cultures
were treated with the indicated drugs, and EGFP-positive cells were scored
for the presence of mitochondria. Error bars indicate standard deviations
from three experiments; 200 cells were scored per experiment. The P-values
were calculated using the t-test.
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For immunoblot analysis, mitochondria were isolated as pre-
viously described (20). For SILAC, mitochondria were iso-
lated from a 1:1 mixture of heavy and light SILAC-labeled,
Parkin-expressing HeLa S3 cells. Cells were lysed using a
nitrogen bomb (Parr) at 200 psi for 10 min, followed by mech-
anical homogenization with a glass–glass dounce homogen-
izer. Crude mitochondria were puriﬁed by differential
centrifugation and further puriﬁed by a discontinuous Percoll
gradient consisting of 80, 52 and 21% Percoll.
Isoelectric focusing of peptides
In-solution digested peptides (150 mg) were separated accord-
ing to their isoelectric point with the Agilent 3100 OFFGEL
fractionator (Agilent). The system was set up according to
the manufacturers’ guidelines (Agilent, 5969-1582), but
strips were exchanged by 13 cm ImmobilineTM DryStrip, pH
3–10 (GE Healthcare), and ampholytes were substituted by
IPG buffer, pH 3–10 (GE Healthcare). Peptides were
focused for 20 kilovolt hours at a maximum current of
50 mA, maximum voltage of 8000 V and maximum power
of 200 mW into 12 fractions. Each peptide fraction was acid-
iﬁed by adding 1% triﬂuoroacetic acid, then desalted and con-
centrated on a reversed-phase C18 StageTips (Proxeon
Biosystems) utilizing a reported adaptation (38). StageTips
were ﬁrst washed with 80% acetonitrile: 0.5% acetic acid,
then methanol, followed by 2% acetonitrile: 1% triﬂouroacetic
acid. Peptides were then loaded onto StageTips, washed with
0.5% acetic acid and eluted with 80% acetonitrile: 0.5%
acetic acid.
Mass spectrometric analysis
All mass spectrometry experiments were performed on an
EASY-nLC connected to a hybrid LTQ–Orbitrap classic
(Thermo Fisher Scientiﬁc) equipped with a nanoelectrospray
ion source (Proxeon Biosystems) essentially as previously
described (39) with some modiﬁcations. Peptides were separ-
ated on a 15 cm reversed-phase analytical column (75 mm
internal diameter) in-house packed with 3 mmC 18 beads
(ReproSil-Pur C18-AQ medium; Dr Maisch GmbH) with a
160 min gradient from 5 to 35% acetonitrile in 0.2% formic
acid at a ﬂow rate of 350 nl per minute. The mass spectrometer
was operated in data-dependent mode to automatically switch
between full-scan MS and tandem MS acquisition. Survey full
scan mass spectra were acquired in the Orbitrap (300–1700 m/z),
after accumulation of 500 000 ions, with a resolution of 60 000
at 400 m/z. The top 10 most intense ions from the survey scan
were isolated and, after the accumulation of 5000 ions, frag-
mented in the linear ion trap by collisionally induced dis-
sociation (collisional energy 35% and isolation width 2 Da).
Precursor ion charge state screening was enabled and all
singly charged and unassigned charge states were rejected.
The dynamic exclusion list was set with a maximum retention
time of 90 s, a relative mass window of 10 ppm and early
expiration was enabled.
Data analysis
Raw data ﬁles were analyzed by MaxQuant (v 1.0.13.13) (40)
and searched against the IPI human database (v 3.54) with
tryptic digestion, maximum of two missed cleavages, ﬁxed
carboxyamidomethyl modiﬁcations of cysteine, variable
oxidation modiﬁcations of methionine and variable protein
N-terminus acetylations with 1% false discovery rate
thresholds for both peptides and proteins. At least two differ-
ent peptide sequences were required for protein identiﬁcation
and two different ratio measurements were required for protein
quantitation. Protein groups whose overall ratios were signiﬁ-
cantly different (P , 0.01) and whose ratios in at least two out
of three replicates were also signiﬁcantly different (P , 0.05)
were considered to be signiﬁcantly altered. Mitochondrial
annotations were derived from MitoCarta (20) and mitochon-
drial outer membrane annotations were derived from Uniprot.
Quantiﬁcation of K48-linked and K63-linked polyubiquitin
was performed by analysis of unique diglycine signature pep-
tides associated with each modiﬁcation (41).
Fluorescence microscopy
All images were acquired using a Plan-Apochromat 63X/1.4
oil objective on a LSM 710 confocal microscope with Zen
2009 software (Carl Zeiss) and processed (to crop out irrele-
vant areas, brightness and contrast adjustment) using ImageJ
software.
Antibodies
The following commercially available antibodies were used:
anti-actin (Mab1501R, Millipore), anti-Bak (Y164, Abcam),
anti-cytochrome c (Mitosciences), anti-F1b (Mitosciences),
anti-Fis1 (Alexis), anti-Hsp60 (SC-1052, Santa Cruz
Biotech), anti-Mfn2 (Sigma), anti-Parkin (PRK8, Cell Signal-
ing), anti-Parkin (Abcam), anti-Psma2 (BioMol), anti-Psmb5
(Abcam), anti-Sod2 (Abcam), anti-Tom20 (FL-145, Santa
Cruz), anti-Tom70 (Novus Biologicals), anti-TRAP-1
(Abcam), anti-ubiquitin (Enzo), anti-K48-polyubiquitin (Cell
Signaling), anti-K63-polyubiquitin (Enzo) and anti-VDAC
(Molecular Probes). The following antibodies were raised
in-house: anti-Opa1 monoclonal 1E8 and anti-Mfn1 (42).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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